T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients (NCT05141058)
🩺 Plain-English Summary (8th-Grade Level)
This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after HSCT). In this dose escalation trial, three doses (1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and \<80 years) HSCT recipients (Arm A) and two arms for pediatric (≥12 years of age and \<18 years; ≥2 years and \<12 years) HSCT recipients (Arm B and Arm C, respectively), and defined dose escalations in each study arm. The study agent will be assessed for safety (stopping rules defined) and antiviral activity.
Who can join: Review the eligibility criteria below.
Location: Children's National Hospital — Washington D.C., District of Columbia
Age range: 2 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Children's National Hospital — Washington D.C., District of Columbia
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (202) 476-5845
Email: sconway@childrensnational.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in SARS-CoV-2 Infection
- Understanding the Long-term Impact of COVID on Children and Families — Birmingham, Alabama
- Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos — San Diego, California
- Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults — Birmingham, Alabama
Explore by condition: All SARS-CoV-2 Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.